Work

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

Year: 2008

Type: article

Source: American Heart Journal

DOI: 10.1016/j.ahj.2008.05.017

Authors: Robert M. Califf, Mitradev Boolell, Steven M. Haffner, M. Angelyn Bethel, John McMurray, Anil Duggal, Rury R. Holman

Institutions: Duke University, Duke Medical Center, Novartis (Switzerland), The University of Texas at San Antonio Health Science Center, Duke Clinical Research Institute, British Heart Foundation, University of Glasgow, Novartis (United States), University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1967140460

FWCI: 9.207

Cites: 45

Cited by: 99

Related to: 10